What markers does the Shield test use compared to OncuraKit?

Shield (Exact Sciences) is FDA-approved specifically for colorectal cancer screening in average-risk adults 45+. It analyzes DNA methylation and cell-free DNA biomarkers from a blood draw. Shield achieved 83% sensitivity for colorectal cancer (all stages) in its approval study, with 83% specificity. However, Shield is single-cancer (colorectal only), requires a prescription and blood draw, and has not published zero data overlap. OncuraKit is a multi-cancer screening test (six cancer types), urine-based, no prescription required, and achieves the highest published Stage I/II sensitivity of any MCED test using three validated miRNA markers. Shield and OncuraKit target different risk profiles and can be complementary — Shield with its FDA approval and CRC focus; OncuraKit with its multi-cancer, no-blood-draw approach.